Search Results 971-980 of 17065 for monoclonal antibody
Monoclonal antibody (ies). At least 28 days since the last dose of monoclonal antibody prior to first dose of tazemetostat. Immunotherapy (e.g., tumor vaccine).
Participants who have received any other monoclonal antibodies ... Participants with any history of hypersensitivity to any monoclonal antibody (including ...
Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown. Anti-immunoglobulin E (IgE) therapy ...
Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a ...
Within 4 weeks (28 days): systemic cytotoxic chemotherapy; small molecule targeted agents with half-life ≥ 7 days; monoclonal antibodies, antibody-drug ...
... monoclonal antibody approved by the FDA for the treatment of relapsing MS, or (iii) rituximab. Qualifying DMTs include: dimethyl fumarate, diroximel ...
Patients receiving any other concomitant CLL directed therapy such as anti-CD20 monoclonal antibody (such as rituximab, ofatumumab or obinutuzumab).
History of severe hypersensitivity reaction to any ingredients of the study treatments (azacitidine or MBG453) or their excipients, or to monoclonal antibodies.
... monoclonal antibody-containing therapy. Note: Relapsed disease is defined as disease that has recurred ≥6 months after completion of therapy. Refractory ...
Lab tests. Lab tests check for antibodies in the immune system that are attacking brain cells and causing seizures.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.